CJ Bioscience Statistics
Total Valuation
CJ Bioscience has a market cap or net worth of KRW 131.96 billion. The enterprise value is 66.00 billion.
Market Cap | 131.96B |
Enterprise Value | 66.00B |
Important Dates
The last earnings date was Thursday, March 20, 2025.
Earnings Date | Mar 20, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
CJ Bioscience has 13.07 million shares outstanding. The number of shares has increased by 30.93% in one year.
Current Share Class | n/a |
Shares Outstanding | 13.07M |
Shares Change (YoY) | +30.93% |
Shares Change (QoQ) | +7.07% |
Owned by Insiders (%) | 3.54% |
Owned by Institutions (%) | 0.09% |
Float | 4.51M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 27.02 |
PB Ratio | 1.27 |
P/TBV Ratio | 2.02 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -2.01 |
EV / Sales | 19.04 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -2.35 |
Financial Position
The company has a current ratio of 4.14, with a Debt / Equity ratio of 0.12.
Current Ratio | 4.14 |
Quick Ratio | 4.10 |
Debt / Equity | 0.12 |
Debt / EBITDA | n/a |
Debt / FCF | -0.33 |
Interest Coverage | -58.29 |
Financial Efficiency
Return on equity (ROE) is -44.00% and return on invested capital (ROIC) is -25.61%.
Return on Equity (ROE) | -44.00% |
Return on Assets (ROA) | -22.44% |
Return on Invested Capital (ROIC) | -25.61% |
Return on Capital Employed (ROCE) | -42.23% |
Revenue Per Employee | n/a |
Profits Per Employee | n/a |
Employee Count | n/a |
Asset Turnover | 0.04 |
Inventory Turnover | 22.21 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -28.82% in the last 52 weeks. The beta is 0.86, so CJ Bioscience's price volatility has been lower than the market average.
Beta (5Y) | 0.86 |
52-Week Price Change | -28.82% |
50-Day Moving Average | 10,399.80 |
200-Day Moving Average | 11,566.35 |
Relative Strength Index (RSI) | 37.48 |
Average Volume (20 Days) | 96,016 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, CJ Bioscience had revenue of KRW 3.47 billion and -32.84 billion in losses. Loss per share was -3,541.00.
Revenue | 3.47B |
Gross Profit | 284.83M |
Operating Income | -34.24B |
Pretax Income | -32.84B |
Net Income | -32.84B |
EBITDA | -29.92B |
EBIT | -34.24B |
Loss Per Share | -3,541.00 |
Balance Sheet
The company has 75.31 billion in cash and 9.35 billion in debt, giving a net cash position of 65.96 billion or 5,048.28 per share.
Cash & Cash Equivalents | 75.31B |
Total Debt | 9.35B |
Net Cash | 65.96B |
Net Cash Per Share | 5,048.28 |
Equity (Book Value) | 77.76B |
Book Value Per Share | 7,969.48 |
Working Capital | 58.24B |
Cash Flow
In the last 12 months, operating cash flow was -27.76 billion and capital expenditures -377.59 million, giving a free cash flow of -28.14 billion.
Operating Cash Flow | -27.76B |
Capital Expenditures | -377.59M |
Free Cash Flow | -28.14B |
FCF Per Share | -2,153.60 |
Margins
Gross Margin | 8.22% |
Operating Margin | -987.76% |
Pretax Margin | -947.28% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
CJ Bioscience does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -30.93% |
Shareholder Yield | -30.93% |
Earnings Yield | -24.88% |
FCF Yield | -21.32% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
CJ Bioscience has an Altman Z-Score of 1.24. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 1.24 |
Piotroski F-Score | n/a |